AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon Plus Dacarbazine For Treatment Of Malignant Melanoma
Published: Sep 14, 2006
NOORDWIJK, The Netherlands & TUCSON, Ariz.--(BUSINESS WIRE)--Sept. 14, 2006--AmpliMed today announced interim results from the ongoing Phase I/II clinical trial of its lead drug candidate Amplimexon® (imexon, inj.) in combination with the drug dacarbazine (DTIC) in patients with advanced malignant melanoma. The results are being presented by study investigator Dr. Jeffrey S. Weber of the USC/Norris Comprehensive Cancer Center at a poster session on September 14th-16th at the Congress of Perspectives in Melanoma X and The Third International Melanoma Research Congress.